

Urogen N.A., Inc. Appoints Terry M. Nida to Chief Operating Officer

Wednesday November 29, 8:30 am - BusinessWire

BURLINGAME, Calif.--(BUSINESS WIRE)--Urogen N.A., Inc. has promoted Terry M. Nida to Chief Operating Officer.

Mr. Nida, aged 58, has 25 years of management experience in the pharmaceutical industry. Since May 2006, he has served as Vice President of Worldwide Sales, Marketing and Corporate Development at Urogen. Prior to joining Urogen, he held the position of Vice President at VIVUS Inc., a pharmaceutical company dedicated to the development and commercialization of therapeutic products, where he was responsible for worldwide corporate development, sales and marketing. Prior to Vivus, Mr. Nida served as Senior Director of Worldwide Sales, Marketing and Business Development for Centocor, Inc., a leader in monoclonal antibody production and technology and a wholly owned subsidiary of Johnson & Johnson. His past work experience also includes positions in sales and marketing at Bristol Laboratories, a division of Bristol Myers, and a distinguished military career.

"We are pleased to promote Terry to this key position," said William J. Garner, President and Chief Executive Officer of Urogen. "Since joining Urogen, Terry has been an integral part of our team and has demonstrated strong leadership skills. We look forward to his continued contributions to the overall growth of the business."

"I consider it a privilege and an honor to be part of Urogen's management team and help lead the Company as it enters such an exciting period in its operating history," said Terry Nida.

About Urogen N.A., Inc.

Urogen N.A., Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urogen has five programs in development that are either in or positioned to enter Phase 2 clinical trials. The pipeline includes U101, for the treatment of Chronic Pelvic Pain (CPP); U102, targeting symptoms of CPP secondary to pelvic irradiation; U103, targeting dyspareunia; U301, targeting acute urethral discomfort; and U302, targeting urethritis. For further information, please visit the Company's website at www.urogen.com.

This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. In particular, forward-looking statements include, without limitation, statements related to the implications of clinical results and prospects for future clinical testing. As with any new pharmaceutical product, there are significant risks in development, regulatory approval and commercialization of Urogen's products. There are no guarantees that future clinical studies will confirm the preliminary results discussed in this press release or that U101 or any other Urogen product or products will receive regulatory approval for any medical condition. Further, even if Urogen were to receive regulatory approval for a product, there can be no assurance that such a product would prove to be commercially successful.

Urogen has previously announced the signing of a merger agreement with Valentis, Inc. (VLTS). Valentis is expected to file with the Securities and Exchange Commission, or the Commission, a Registration Statement on Form S-4, which will include a joint proxy statement/prospectus of Valentis and Urogen and other relevant materials in connection with the proposed transaction. The

joint proxy statement/prospectus will be mailed to the stockholders of Valentis and Urogen. Investors and security holders of Valentis and Urogen are urged to read the joint proxy statement/prospectus and the other relevant materials when they become available because they will contain important information about Valentis, Urogen and the proposed merger. The joint proxy statement/prospectus and other relevant materials (when they become available), and any other documents filed by Valentis or Urogen with the Commission, may be obtained free of charge at the Commission's web site at www.sec.gov. Investors and security holders are urged to read the joint proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction.

With respect to the proposed merger additional risks include: the future financial condition of Valentis (either before or after the merger), the continued qualification of the common stock of Valentis for listing on the Nasdaq Capital Market (either before or after the merger), risks associated with the discontinuance of the existing Valentis operations, risks associated with unsatisfactory results from the clinical trials of Urogen products, the successful integration of Valentis and Urogen, costs and potential litigation associated with the merger, industry-wide changes and other causes, the risk that the transaction may not be completed, the failure of either party to meet the closing conditions set forth in the merger agreement or that the closing of the transaction may be delayed due to failure to obtain required approvals. These and other important factors to be discussed in the joint proxy statement/prospectus may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on any forward-looking statements. Urogen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Urogen and its respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Valentis and Urogen in favor of the proposed merger. Information about the directors and executive officers of Urogen and their respective interests in the proposed merger will be available in the joint proxy statement/prospectus. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. This press release does not constitute an offer of any securities for sale or the solicitation of any proxy.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

SOURCE: Urogen N.A., Inc.

Urogen N.A., Inc.
Martin Shmagin
Chief Financial Officer
Phone: 415-971-1080
www.urogen.com

The Investor Relations Group
Investor Relations: Katrine Winther-Olesen
Media Contacts: Janet Vasquez / Lynn Granito
Phone: 212-825-3210